Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.700
+0.200 (8.00%)
At close: Jun 11, 2026, 4:00 PM EDT
2.660
-0.040 (-1.48%)
After-hours: Jun 11, 2026, 7:36 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,492,353
Market Cap
14.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| BioLineRx | 24 |
| Jasper Therapeutics | 22 |
| OSR Holdings | 22 |
| IN8bio | 17 |
| BioVie | 13 |
| Cocrystal Pharma | 10 |
| Phio Pharmaceuticals | 6 |
MBRX News
- 6 days ago - Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML - GlobeNewsWire
- 7 days ago - Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment - GlobeNewsWire
- 13 days ago - Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits - GlobeNewsWire
- 21 days ago - Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - GlobeNewsWire
- 27 days ago - Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewsWire
- 4 weeks ago - Moleculin Biotech Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Moleculin Biotech Earnings release: Q1 2026 - Filings
- 4 weeks ago - Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30 - TheFly